Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation using its proprietary degrader platform to develop oral small molecule therapies. The company's lead programs target immunological diseases (KT-474 for atopic dermatitis and hidradenitis suppurativa) and oncology (KT-333 for hematologic malignancies), with multiple candidates in Phase 1/2 trials as of early 2026. The stock trades on clinical trial readouts, partnership announcements, and capital runway visibility rather than commercial revenues.
Kymera operates a platform-based drug discovery model focused on heterobifunctional degraders that hijack the cell's natural protein disposal system. The company monetizes through upfront payments, research funding, milestone payments, and future royalties from pharmaceutical partnerships while advancing wholly-owned programs. Current burn rate approximately $200M annually supports 4-5 clinical programs and platform expansion. The degrader modality offers potential advantages over traditional inhibitors including addressing 'undruggable' targets, overcoming resistance mechanisms, and achieving tissue selectivity. Value creation depends on demonstrating clinical proof-of-concept in lead indications, which could trigger substantial milestone payments or acquisition interest from large pharma seeking novel mechanisms.
Clinical trial data readouts for KT-474 (IRAK4 degrader) in atopic dermatitis Phase 2 and hidradenitis suppurativa trials
KT-333 (STAT3 degrader) efficacy and safety data in hematologic malignancies
New partnership announcements or expansion of existing collaborations (e.g., Sanofi alliance modifications)
Pipeline expansion announcements including IND filings for preclinical programs
Capital raises, cash runway updates, and quarterly burn rate guidance
Competitive developments in protein degradation space from Arvinas, C4 Therapeutics, Nurix, or large pharma entrants
Clinical trial failure risk - Phase 2 attrition rates for novel mechanisms exceed 70%, with protein degradation modality still establishing clinical validation across indications
Regulatory pathway uncertainty for degrader class - FDA may require additional safety studies given novel mechanism involving ubiquitin-proteasome system modulation
Platform technology risk - if degrader approach fails to demonstrate advantages over traditional small molecules, entire thesis undermined
Capital intensity - estimated $500M+ required to advance lead programs through Phase 3, necessitating future dilutive financings or partnerships that reduce economics
Large pharmaceutical companies (Roche, Novartis, Bristol Myers Squibb) developing internal degrader capabilities, reducing partnership value and acquisition premiums
Competing degrader biotechs (Arvinas with ARV-110/471, C4 Therapeutics, Nurix) advancing similar mechanisms, potentially validating space but commoditizing platform
Superior competing mechanisms for IRAK4 inhibition (Eli Lilly, Pfizer programs) or STAT3 targeting could render Kymera's degraders non-competitive
Patent landscape complexity around heterobifunctional degraders may limit freedom to operate or enable competitor workarounds
Cash runway risk - current burn rate of ~$200M annually implies 7+ years of runway at current cash levels, but accelerating development could compress timeline
Dilution risk from future equity raises - typical biotech requires multiple financings before commercialization, with dilution risk elevated if raised during market downturns
Minimal debt provides flexibility but also means limited non-dilutive capital options beyond partnerships
low - Pre-revenue biotech with minimal direct GDP sensitivity. Clinical trial timelines and regulatory processes largely insulated from economic cycles. However, severe recessions can impact: (1) ability to raise capital at attractive valuations, (2) pharmaceutical partners' willingness to fund collaborations, and (3) acquisition appetite from strategic buyers. Patient enrollment can be affected by healthcare access during downturns, though rare disease trials less impacted.
Rising rates create significant valuation pressure on pre-revenue biotechs through higher discount rates applied to distant cash flows (potential revenues 3-7+ years out). Higher rates also increase opportunity cost of holding cash-burning equities versus risk-free alternatives. Conversely, the company benefits from higher yields on its substantial cash balance (~$1.4B estimated based on current ratio). Financing costs minimal given low debt/equity of 0.09. Rate environment heavily influences biotech sector sentiment and M&A valuations.
Minimal direct credit exposure given negligible debt (0.09 debt/equity ratio) and strong liquidity position. However, credit market conditions indirectly affect: (1) ability to access capital markets for future financings, (2) valuation multiples for biotech sector, and (3) pharmaceutical industry M&A activity. Widening credit spreads often correlate with risk-off sentiment that pressures speculative growth stocks including clinical-stage biotechs.
growth - Attracts high-risk tolerance investors seeking asymmetric returns from novel therapeutic modalities. Typical holders include specialized healthcare hedge funds, biotech-focused venture capital, and growth-oriented institutional investors willing to underwrite binary clinical outcomes. The 128.7% one-year return and high volatility profile appeal to momentum traders around data catalysts. Not suitable for income investors (no dividend) or value investors (no earnings, extreme valuation multiples). Recent 94.6% six-month surge suggests strong momentum investor participation.
high - Clinical-stage biotech with binary event risk around trial readouts creates extreme volatility. Stock can move 30-50%+ on single data releases. Pre-revenue status and lack of fundamental anchors amplify sentiment-driven swings. High beta to biotech sector (XBI) and growth stock indices. Volatility elevated by relatively modest market cap ($6.7B) and potential liquidity constraints during risk-off periods. Options market typically prices elevated implied volatility ahead of known catalysts.
